MoonLake Immunotherapeutics MLTX Other Working Capital
Other Working Capital at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's other working capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's other working capital?
- MoonLake Immunotherapeutics (MLTX) reported other working capital of -$422K in Q1 2026.
- How has MoonLake Immunotherapeutics's other working capital changed year-over-year?
- MoonLake Immunotherapeutics's other working capital decreased by 240.3% year-over-year, from -$124K to -$422K.
- What is the long-term trend for MoonLake Immunotherapeutics's other working capital?
- Over 2 years (2022 to 2024), MoonLake Immunotherapeutics's other working capital has grown at a 90.0% compound annual growth rate (CAGR), from -$68.45K to $247K.
- What does other working capital mean?
- Net change in working capital items not separately classified — a residual balancing item.